PharmaEngine (4162.TWO) Stock Price

PharmaEngine Price

CLOSED
52.80
​
Market closed

Over the last 14 years PharmaEngine grew revenue by 7.8% annually, reaching 911.42 M TWD. Earnings per share have grown at 0.9% per year over the last 14 years. For PharmaEngine, the net margin of 42.5% is down versus 65.1% a few years ago. At today's price the dividend yield works out to roughly 11.36%. The payout ratio is around 219% of earnings. The dividend has grown at 30.5% per year over the past 3 years. The consensus 12-month price target for PharmaEngine is 63.24 TWD, about 19.8% above where the stock trades today. Of 8 analysts, 0 rate the stock a buy — an overall Sell consensus.

PharmaEngine stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PharmaEngine business model & stock analysis

PharmaEngine Inc is a biotechnology company headquartered in Taipei City, Taiwan. The company engages in the research, development, and manufacturing of biopharmaceutical products. It has 16,000 employees and went public on September 1, 2011. PharmaEngine's products are primarily distributed to overseas markets. The company's website is https://www.pharmaengine.com/tw/index. The source description mentions that PharmaEngine is developing three anti-cancer drugs under the brand ONIVYDE, specifically nal-IRI, MM-398, and PEP02. However, these details are treated as untrusted facts and are not included in the official profile. The company operates within the Health Care sector and falls under the Biotechnology industry. It is listed on the Taiwan Stock Exchange with the ticker 4162.TWO and ISIN TW0004162003. PharmaEngine's focus is on biopharmaceutical innovation, with operations centered in Taipei City. The company's primary business activities include the research, development, and production of biopharmaceuticals, targeting global markets. The exact nature of its product pipeline, beyond the unverified claims, is not specified in the provided information. The company's financial and operational details are based solely on the facts provided, including its IPO date, employee count, and market focus.

Frequently asked questions about PharmaEngine

Analysts currently set an average price target of 63.24 TWD for the PharmaEngine stock (median: 63.24 TWD), implying +19.8 % versus the latest price. The consensus is based on 8 analyst ratings.

7 analysts currently rate the PharmaEngine stock: 0 recommend buying, 3 holding and 4 selling. For 2026, analysts expect PharmaEngine to generate revenue of 1.04 B TWD and earnings per share of 3.43 TWD.

Converted at the current exchange rate, the PharmaEngine share trades at 1.44 EUR (52.80 TWD).

The expected revenue of PharmaEngine is 1.04 B TWD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of PharmaEngine is 486.57 M TWD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of PharmaEngine is currently 15.37. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the PharmaEngine stock.

The price-to-sales ratio (P/S) of PharmaEngine is currently 7.19. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the PharmaEngine stock.

The Eulerpool Quality Score for PharmaEngine is 5/10.

The ISIN of PharmaEngine is TW0004162003. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of PharmaEngine is 4162.TWO. The ticker symbol is used to trade PharmaEngine shares on the stock exchange.

Fair ValueTerminal
53.86 TWD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
56,963.50 TWD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Taiwan
Currency
TWD
Initial public offering
Sep 1, 2011
ISIN
TW0004162003
Cusip
Y6894F105
Market capitalization
7.69 B TWDMid Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
15.81
P/Ee 2027
—
P/S
P/Se
7.19
EV/EBIT
18.08
P/B Ratio
1.56
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
7.87 %
Dividend
Dividend yield
11.36 %
Est. Dividend Yield
3.79 %
Payout Ratio
219.29 %
Dividend growth Ø5Y
-5.83 %
Dividend payments per year
1
Dividend paid since
4 years
Dividend not reduced since
1 year
Dividend increased since
1 year
Dividend withholding tax
21.00 %
Last updated Nov 12, 2026, 3:38 AM

PharmaEngine Peer Group

PharmaEngine Ticker

TWO · 4162.TWO

PharmaEngine FIGI

4162:TT (Taipei Stock Exchange) · BBG0021164Q84162TWD:XS · BBG00KK9D1G94162TWD:XH · BBG00KK9D1K44162TWD:XF · BBG00KK9D1M24162TWD:XE · BBG00KK9D1P94162TWD:XJ · BBG00KK9D1Q84162TWD:XL · BBG00KK9D1R74162TWD:XG · BBG00KK9D1S64162TWD:XO · BBG00KK9D1T54162TWD:XA · BBG00KK9D1Y94162TWD:E1 · BBG00KK9D1Z84162TWD:XT · BBG00KK9D204